Mutations in the NS5A gene are associated with response to interferon+ribavirin combination therapy in patients with chronic hepatitis C virus 3a infection

European Journal of Gastroenterology and Hepatology

Volumn 25, Issue 10, 2013, Pages 1146-1151

  Ullah, Sajjad ^a   Rehman, Habib U ^b   Idrees, Muhammad ^a  

^a UNIVERSITY OF THE PUNJAB   (Pakistan)

^b Mardan Medical Complex Teaching Hospital   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

HOST FACTOR; NONSTRUCTURAL PROTEIN 5A; RECOMBINANT ALPHA INTERFERON; RIBAVIRIN; VIRUS RNA;

ADOLESCENT; ADULT; AGE; AGED; ANTIVIRAL THERAPY; BLOOD TRANSFUSION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DENTAL SURGERY; DISEASE DURATION; DRUG WITHDRAWAL; FEMALE; GENDER; GENE MUTATION; GENETIC ASSOCIATION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFECTION RISK; MAJOR CLINICAL STUDY; MAJOR SURGERY; MALE; MINOR SURGERY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RELAPSE; REVIEW; TREATMENT RESPONSE; VIRUS LOAD; VIRUS STRAIN; VIRUS TRANSMISSION;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ANTIVIRAL AGENTS; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; MUTATION; PHYLOGENY; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; RIBAVIRIN; SEX FACTORS; TREATMENT OUTCOME; VIRAL LOAD; VIRAL NONSTRUCTURAL PROTEINS; YOUNG ADULT;

EID: 84883657340     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0b013e328360aeb4     Document Type: Review

References (24)

1. Alter MJ, Margolis HS, Krawczynski K, Judson F.N., Mares A., Alexander WJ, et al The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. N Engl J Med 1992; 327:1899-1905. (Pubitemid 23006964)
2. Aman MJG, Rudolf J, Goldschmitt W.E., Aulitzky C., Lam C, Huber C, Peschel C. Type-I interferons are potent inhibitors of interleukin-8 production in hematopoietic and bone marrow stromal cells. Blood 1993; 15:2371-2378. (Pubitemid 23304260)
3. De Vos J.M., Jourdan K, Tarte C., Jasmin C, Klein B. JAK2 tyrosine kinase inhibitor tyrphostin AG 490 downregulates the mitogen-activated protein Kinase (MAPK) and signal transducer and activator of transcription (STAT) pathways and induces apoptosis I myeloma cells. Br J Haematol 2000; 109:823-828. (Pubitemid 30609763)
4. 0 untranslated region of eukaryotic transcripts. Curr Opin Cell Biol 1995; 7:386-392.
5. Elazar M, Cheong KH, Liu P, Greenberg H.B., Rice CM, Glenn JS Amphipathic helix-dependent localization of NS5A mediates hepatitis C virus RNA replication. J Virol 2003; 77:6055-6061. (Pubitemid 36546191)
6. Khabar KSA, Al-Zoghaibi MN, Al-Ahdal T, Murayama M., Dhalla N, Mukaida M, et al The alpha chemokine, interleukin 8, inhibits the antiviral action of interferon alpha. J Exp Med 2004; 186:1077-1085.
7. McHutchison JG, Gordon SC, Schiff E.R., Shiffman ML, Lee WM, Rustgi VK, et al Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339:1485-1492. (Pubitemid 28543496)
8. Poynard T, Marcellin P, Lee S.S., Niederau C., Minuk GS, Ideo G, et al Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352:1426-1432. (Pubitemid 28510876)
9. Reichard O, Norkrans G, Fryden A., Braconier JH, Sonnerborg A, Weiland O. Comparison of 3 quantitative HCV RNA assays - accuracy of baseline viral load to predict treatment outcome in chronic hepatitis C. Scand J Infect Dis 1998; 30:441-446. (Pubitemid 29054344)
10. Sim H, Yim C, Krajden M., Heathcote J. Durability of serological remission in chronic hepatitis C treated with interferon-alpha-2B. Am J Gastroenterol 1998; 93:39-43. (Pubitemid 29065510)
11. Hayashi S, Saeki S, Hosoi H., Tanaka T, Shibayama T, OoTake H., et al. A clinical and portal hemodynamic analysis for obliteration of gastric-renal shunt communicated with gastric fundic varices [in Japanese]. Nihon Shokakibyo Gakkai Zasshi 1998; 95:755-763.
12. Feld JJ, Hoofnagle JH Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 2005; 436:967-972. (Pubitemid 41191673)
13. 0-oligoadenylate synthetase gene by hepatitis C virus core protein. J Virol 2004; 74:8744-8750.
14. Squadrito G, Leone F, Sartori M., Nalpas B, Berthelot P, Raimondo G., et al. Mutations in the nonstructural 5A region of hepatitis C virus and response of chronic hepatitis C to interferon alfa. Gastroenterology 1997; 113:567-572. (Pubitemid 27351784)
15. Enomoto NI, Sakuma Y, Asahina M., Kurosaki T, Murakami C, Yamamoto Y., et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 1996; 334:77-81.
16. Macquillan GC, Niu X, Speers D., English S, Garas G, Harnett G.B., et al. Does sequencing the PKRBD of hepatitis C virus NS5A predict therapeutic response to combination therapy in an Australian population? J Gastroenterol Hepatol 2004; 19:551-557. (Pubitemid 38669903)
17. Sarrazin C, Bruckner M, Herrmann E., Ruster B, Bruch K, Roth W.K., Zeuzem S. Quasispecies heterogeneity of the carboxy-terminal part of the E2 gene including the PePHD and sensitivity of hepatitis C virus 1b isolates to antiviral therapy. Virology 2002; 289:150-163. (Pubitemid 33016246)
18. Idrees M, Riazuddin S. Frequency distribution of hepatitis c virus genotypes in different geographical regions of Pakistan and their possible routes of transmission. BMC Infect Dis 2008; 8:69.
19. Kwok S, Higuchi R. Avoiding false positives with PCR. Nature 1989; 339:237-238.
20. Pakistan Medical Research Council website. Homepage of Pakistan Medical Research Council. Available at: http://www.pmrc.org.pk/hepatitisbc.htm [Accessed 21 January 2009].
21. Idrees M, Lal A, Naseem M., Khalid M. High prevalence of hepatitis C virus infection in the largest province of Pakistan. J Dig Dis 2008; 9:95-103. (Pubitemid 351566631)
22. Idrees M, Riazuddin S. A study of best positive predictors for sustained virologic response to interferon alpha plus ribavirin therapy in naive chronic hepatitis C patients. BMC Gastroenterol 2009; 9:5.
23. Kohashi TS, Maekawa N, Sakamoto M., Kurosaki H, Watanabe Y, Tanabe C.H., et al. Site-specific mutation of the interferon sensitivity-determining region (ISDR) modulates hepatitis C virus replication. J Viral Hepat 2006; 13:582-590.
24. Raza A, Zaman N, Arshad B.G., Asad MA, Aziz H, Qureshi SN Mutations in ISDR may be linked to high viremia and virus resistance to IFN-alpha-2b but responsive to PEG-IFN-alpha-2a. Int J Sci Emerging Tech 2012; 4:154-158.